Education
About Us
Working with TipRanks
Follow Us
Verona Pharma (VRNA)
:VRNA
VRNA Stock Chart & Stats
$106.91
$0.12(0.11%)
―
--
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Product InnovationOhtuvayre, a first-in-class selective dual inhibitor of PDE3 and PDE4, is the first novel inhaled mechanism for the treatment of COPD in more than 20 years, offering bronchodilator and non-steroidal anti-inflammatory effects.
Revenue GrowthSince its approval and commercial launch, Ohtuvayre has established strong revenue growth, showing a fast adoption among physicians and patients.
Bears Say
Financial PerformanceIncreased costs have been modeled, resulting in a reduction in net income for 2025.
Market PerceptionIn the wake of the deal announcement, the rating was downgraded to Neutral from the prior Buy.
Verona Pharma News
VRNA FAQ
What was Verona Pharma’s price range in the past 12 months?
Currently, no data Available
What is Verona Pharma’s market cap?
Currently, no data Available
When is Verona Pharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Verona Pharma’s earnings last quarter?
Verona Pharma released its earnings results on Jul 31, 2025. The company reported -$0.005 earnings per share for the quarter, missing the consensus estimate of $0.029 by -$0.034.
Is Verona Pharma overvalued?
According to Wall Street analysts Verona Pharma’s price is currently Undervalued.
Does Verona Pharma pay dividends?
Verona Pharma does not currently pay dividends.
What is Verona Pharma’s EPS estimate?
Verona Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Verona Pharma have?
Currently, no data Available
What happened to Verona Pharma’s price movement after its last earnings report?
Verona Pharma reported an EPS of -$0.005 in its last earnings report, missing expectations of $0.029. Following the earnings report the stock price went down -0.048%.
Which hedge fund is a major shareholder of Verona Pharma?
Currently, no hedge funds are holding shares in VRNA
Company Description
Verona Pharma
Verona Pharma (VRNA) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases. The company is primarily involved in the research and development of novel compounds that target unmet medical needs in conditions such as chronic obstructive pulmonary disease (COPD) and asthma. Verona Pharma's lead product candidate, ensifentrine, is an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, designed to improve lung function and reduce inflammation.